Evidence map›Paper›PMID 41897522›Full record

ReviewAntioxidants (Basel, Switzerland)2026

A Review of HIF-1α-Mediated Integration of Metabolic Reprogramming, Mitochondrial Function, and PI3K/Akt-MAPK-Nrf2-NF-κB Signaling.

Asha Ashraf, Erica D Bruce

Abstract readReview
In one paragraph

Review in Antioxidants (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed.

  1. Article
  2. Antioxidants (Basel, Switzerland) · 2026
    Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Review
  9. Article
  10. Review
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Asha AshrafDepartment of Environmental Science, Baylor University, 101 Bagby Ave., Waco, TX 76706, USA.ORCID 0009-0006-3890-8104
Erica D BruceDepartment of Environmental Science, Baylor University, 101 Bagby Ave., Waco, TX 76706, USA.ORCID 0000-0002-4900-0496

Funding

C. Gus Glasscock, Jr. Endowed Fund for Excellence in Environmental Sciences 000002025
6 · The paper itself

Abstract

Hypoxia is a common feature of many physiological and pathological conditions, including inflammation, ischemia, and chronic lung disease, where limited oxygen availability disrupts mitochondrial metabolism and promotes excessive reactive oxygen species (ROS) generation. Hypoxia-inducible factor-1α (HIF-1α) is the central transcriptional regulator that enables cellular adaptation to low-oxygen environments by coordinating metabolic reprogramming, mitochondrial remodeling, and redox control. While HIF-1α is widely recognized for its role in promoting glycolysis, evidence indicates that it also suppresses mitochondrial ROS production through coordinated regulation of mitochondrial metabolism, biogenesis, and quality control. This review examines how HIF-1α integrates these mitochondrial and redox-adaptive mechanisms and highlights its bidirectional interactions with key stress-responsive signaling pathways, including PI3K/Akt, MAPK, Nrf2, and NF-κB, that together shape metabolic adaptation, inflammatory responses, and cell survival under hypoxic stress. By integrating these diverse mechanisms, this review provides a comprehensive understanding of the pathophysiology of hypoxia-associated diseases and underscores the therapeutic potential of targeting HIF-1α-regulated metabolic and inflammatory pathways to mitigate oxidative damage induced by hypoxia and environmental stressors.

Indexed as

hypoxiahypoxia-inducible factor-1α (HIF-1α)MAPKmitochondrial metabolismNF-κBNrf2oxidative stressPI3K/Aktreactive oxygen species (ROS)

Identifiers

PMID41897522
PMCPMC13023740

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.